Baseline characteristic of the study cohorts
| Characteristics . | Cohort 1 (n = 385) . | Cohort 2 (n = 56) . | P value . |
|---|---|---|---|
| Age at diagnosis, median (IQR) | 59 (55-65) | 62 (57-68) | .01 |
| Age at ASCT, median (IQR) | 60 (55-65) | 63 (58-68) | .009 |
| Time from diagnosis to ASCT, n (%) | |||
| >6 mo | 166 (43.1) | 39 (69.6) | <.001 |
| >12 mo | 54 (14) | 19 (33.4) | <.001 |
| Disease status at ASCT, n (%) | <.001 | ||
| Newly-diagnosed disease | 351 (91.2) | 41 (73.2) | |
| Relapsed/refractory disease | 34 (8.8) | 15 (26.9) | |
| Male gender, n (%) | 240 (62.3) | 29 (51.8) | .13 |
| Lambda light chain isotype, n (%) | 263 (68.3) | 41 (73.2) | .45 |
| Heavy chain isotype, n (%) | |||
| IgG | 149 (38.7) | 24 (42.9) | <.001 |
| IgA | 36 (9.4) | 11 (19.6) | |
| IgM | 19 (4.9) | 6 (10.7) | |
| IgD | 1 (0.3) | 2 (3.6) | |
| No heavy chain association | 180 (46.7) | 13 (23.2) | |
| No. of organs involved, n (%) | .78 | ||
| 1 | 200 (51.9) | 28 (50) | |
| >1 | 185 (48.1) | 28 (50) | |
| Involved organs, n (%) | |||
| Kidney involvement | 230 (59.7) | 30 (53.6) | .38 |
| Heart involvement | 184 (47.8) | 29 (52.8) | .57 |
| Gastrointestinal involvement | 61 (15.8) | 8 (14.6) | .8 |
| Peripheral nerve involvement | 47 (12.2) | 7 (12.5) | .95 |
| Autonomic nerve involvement | 42 (10.9) | 7 (12.5) | .72 |
| Liver involvement | 38 (9.9) | 2 (3.6) | .09 |
| Baseline dFLC (mg/L), median (IQR) | 165 (61-553) | 189 (85-604) | .72 |
| Baseline BMPCs (%), median (IQR) | 8 (5-15) | 14 (6-30) | .008 |
| Cardiac stage at baseline, 1/2/3A/3B, % | 44/44/10/2 | 40/38/16/6 | .28 |
| Cardiac stage at ASCT, 1/2/3A/3B, % | 43/45/9/3 | 37/45/14/4 | .64 |
| ECOG PS at ASCT, 0/1/2-3, % | 46/51/3 | 19/81/0 | .01 |
| Characteristics . | Cohort 1 (n = 385) . | Cohort 2 (n = 56) . | P value . |
|---|---|---|---|
| Age at diagnosis, median (IQR) | 59 (55-65) | 62 (57-68) | .01 |
| Age at ASCT, median (IQR) | 60 (55-65) | 63 (58-68) | .009 |
| Time from diagnosis to ASCT, n (%) | |||
| >6 mo | 166 (43.1) | 39 (69.6) | <.001 |
| >12 mo | 54 (14) | 19 (33.4) | <.001 |
| Disease status at ASCT, n (%) | <.001 | ||
| Newly-diagnosed disease | 351 (91.2) | 41 (73.2) | |
| Relapsed/refractory disease | 34 (8.8) | 15 (26.9) | |
| Male gender, n (%) | 240 (62.3) | 29 (51.8) | .13 |
| Lambda light chain isotype, n (%) | 263 (68.3) | 41 (73.2) | .45 |
| Heavy chain isotype, n (%) | |||
| IgG | 149 (38.7) | 24 (42.9) | <.001 |
| IgA | 36 (9.4) | 11 (19.6) | |
| IgM | 19 (4.9) | 6 (10.7) | |
| IgD | 1 (0.3) | 2 (3.6) | |
| No heavy chain association | 180 (46.7) | 13 (23.2) | |
| No. of organs involved, n (%) | .78 | ||
| 1 | 200 (51.9) | 28 (50) | |
| >1 | 185 (48.1) | 28 (50) | |
| Involved organs, n (%) | |||
| Kidney involvement | 230 (59.7) | 30 (53.6) | .38 |
| Heart involvement | 184 (47.8) | 29 (52.8) | .57 |
| Gastrointestinal involvement | 61 (15.8) | 8 (14.6) | .8 |
| Peripheral nerve involvement | 47 (12.2) | 7 (12.5) | .95 |
| Autonomic nerve involvement | 42 (10.9) | 7 (12.5) | .72 |
| Liver involvement | 38 (9.9) | 2 (3.6) | .09 |
| Baseline dFLC (mg/L), median (IQR) | 165 (61-553) | 189 (85-604) | .72 |
| Baseline BMPCs (%), median (IQR) | 8 (5-15) | 14 (6-30) | .008 |
| Cardiac stage at baseline, 1/2/3A/3B, % | 44/44/10/2 | 40/38/16/6 | .28 |
| Cardiac stage at ASCT, 1/2/3A/3B, % | 43/45/9/3 | 37/45/14/4 | .64 |
| ECOG PS at ASCT, 0/1/2-3, % | 46/51/3 | 19/81/0 | .01 |
BMPCs, bone marrow plasma cells; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; IgG, immunoglobulin G.
Statistically significant results (P < .05) are shown in bold.